News

-Toward Early Diagnosis and the Development of Novel Therapies –

Human Life CORD Japan Inc. (Head Office: Chuo-ku, Tokyo; President & CEO: Masamitsu Harata; hereinafter “HLC”), a company pioneering the practical application and global deployment of umbilical cord–derived mesenchymal stromal cells (UC-MSCs) as regenerative medicine products, today announced the completion of subject enrollment and blood sample collection for biomarker measurement in its ongoing sarcopenia clinical research in Brazil. A total of 70 subjects, the target for this study, have been successfully registered.

This study, conducted in collaboration with the Federal University of Rio Grande do Sul (UFRGS) since January 2025, aims to identify biomarkers that can serve as indicators of disease progression and therapeutic efficacy for sarcopenia—an age-related condition characterized by the decline of muscle mass and strength—and to evaluate the potential efficacy of UC-MSCs. With enrollment now complete, data analysis is expected to be finalized within this year. The resulting findings are anticipated to accelerate the development of future therapies utilizing UC-MSCs.

Sarcopenia, recognized under the International Classification of Diseases (ICD), is one of the most pressing age-related health challenges in aging societies. While no effective treatment has yet been established, the identification of objective biomarkers is essential for enabling early diagnosis and timely therapeutic intervention. The progress of this study represents a significant milestone in generating internationally applicable data, further advancing the prospects for global clinical development.

HLC will continue to drive the development of UC-MSCs–based therapies for sarcopenia, while strengthening international collaborations and standardizing manufacturing processes in Japan and the United States. Through these efforts, the company is committed to contributing to the extension of healthy life expectancy and improved quality of life (QOL) for aging populations worldwide.

________________________________________

About the Federal University of Rio Grande do Sul (UFRGS)
(http://www.ufrgs.br/english/home)
Founded in 1934, the Federal University of Rio Grande do Sul (UFRGS) is a leading public university in Brazil, widely recognized for its excellence in education and research. The university has an outstanding track record across diverse academic disciplines, particularly in medicine, where it has demonstrated global leadership in aging and age-related disease research. Leveraging Brazil’s rich cultural and ethnic diversity, UFRGS conducts wide-ranging data collection and advanced research initiatives.
 
About Human Life CORD Japan Inc.
(https://humanlifecord.com/en/)
Human Life CORD, Inc. develops and manufactures umbilical cord-derived cell products that can be domestically sourced and cryopreserved in Japan. Our mission is to transform umbilical cords—often discarded after birth—into sources of life-saving cell therapies for patients with unmet medical needs, and eventually into preventive medicine that extends healthy life expectancy. Awards include: Tokyo Venture Championship Grand Prize & Governor of Tokyo Award (2019), Japan Open Innovation Award – Minister of Health, Labour and Welfare Award (2023), J-Startup selected company (2023), and the Tokyo Chamber of Commerce and Industry “Courageous Management Award” – Startup Division Grand Prize (2024).
________________________________________

[Contact for Media Inquiries]
Public Relations, Human Life CORD Japan Inc.
Attn: Yuki Hayashi
TEL: +81-80-4671-0405
Email: info@humanlifecord.com